Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer by Sherrill, B et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q-TWiST analysis of lapatinib combined with capecitabine for the
treatment of metastatic breast cancer
Citation for published version:
Sherrill, B, Amonkar, MM, Stein, S, Walker, M, Geyer, C & Cameron, D 2008, 'Q-TWiST analysis of
lapatinib combined with capecitabine for the treatment of metastatic breast cancer' British Journal of
Cancer, vol. 99, no. 5, pp. 711-5. DOI: 10.1038/sj.bjc.6604501
Digital Object Identifier (DOI):
10.1038/sj.bjc.6604501
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
British Journal of Cancer
Publisher Rights Statement:
Copyright 2008, Cancer Research UK. BJC Open article
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Q-TWiST analysis of lapatinib combined with capecitabine for the
treatment of metastatic breast cancer
B Sherrill*,1, MM Amonkar2, S Stein2, M Walker3, C Geyer4 and D Cameron5
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The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine
monotherapy in women with previously treated HER2þ metastatic breast cancer (MBC). The quality-adjusted time without
symptoms of disease or toxicity of treatment (Q-TWiST) method was used to compare treatments. The area under survival curves
was partitioned into health states: toxicity (TOX), time without symptoms of disease progression or toxicity (TWiST), and relapse
period until death or end of follow-up (REL). Average times spent in each state, weighted by utility, were derived and comparisons of
Q-TWiST between groups performed with varying combinations of the utility weights. Utility weights of 0.5 for both TOX and REL,
that is, counting 2 days of TOX or REL as 1 day of TWiST, resulted in a 7-week difference in quality-adjusted survival favouring
combination therapy (P¼ 0.0013). The Q-TWiST difference is clinically meaningful and was statistically significant across an entire
matrix of possible utility weights. Results were robust in sensitivity analyses. An analysis with utilities based on EQ-5D scores was
consistent with the above findings. Combination therapy of lapatinib with capecitabine resulted in greater quality-adjusted survival
than capecitabine monotherapy in trastuzumab-refractory MBC patients.
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Lapatinib (Tykerb/Tyverb) combined with capecitabine (Xeloda)
has been shown to significantly delay disease progression, as
compared with capecitabine alone, in women with HER2þ
(ErbB2þ ) metastatic breast cancer that has progressed after
standard therapies of anthracyclines, taxanes and trastuzumab
(Geyer et al, 2006; Cameron et al, 2008). The combination therapy
of lapatinib with capecitabine resulted in similar types of adverse
events (AEs), and no increase in serious toxic effects, as compared
with capecitabine monotherapy. These previously reported ana-
lyses focus on efficacy and safety outcomes independently. In a
cancer setting it becomes important to compare treatment risks
and benefits within a single metric.
We therefore conducted a quality-adjusted time without
symptoms of disease or toxicity of treatment (Q-TWiST) analysis,
to better estimate the overall benefit for patients using a single
metric that incorporates progression, survival, treatment toxicities
and quality-of-life. Originally developed for evaluating breast
cancer treatments, this quality-adjusted survival method describes
both the quality and quantity of survival time using a single metric
(Gelber and Goldhirsch, 1986; Gelber et al, 1991). Q-TWiST
compares the relative therapeutic value of treatments based on the
patient experience within the context of clinical outcomes related
to cancer and its treatment. Thus, Q-TWiST provides a measure
of clinical benefit not necessarily apparent from separate efficacy
and safety assessments. Assessments such as time to disease
progression measure the length of time between clinical events but
do not account for the value of that time to the patient.
The Q-TWiST method assumes that cancer patients progress
through a set of health states of varying utility value for the
individual patient. The health states most commonly used for
Q-TWiST analyses of cancer treatment studies include: toxicity
(TOX), time spent with toxic effects of study treatment; TWiST,
time period without either symptoms of disease progression or
toxicity; and relapse (REL), time following disease progression
until death or end of follow-up (Cole et al, 2001).
Quality-adjusted survival is an understandable concept and can
help individual patients make informed treatment decisions based
on the relative importance they place on different health outcomes.
Comparison of the amount of time a patient can expect before
relapse without debilitating toxicities is a valuable aid in choosing
between treatments. In this particular application, we were interested
in showing whether patients on the combination of lapatinib and
capecitabine would experience on average more time in a better
health state compared with patients on capecitabine alone.
MATERIALS AND METHODS
Data source
The data source for this analysis was the previously reported Phase
III clinical trial of lapatinib combined with capecitabine vs
capecitabine alone in women with advanced or metastatic HER2þ
breast cancer who had progressive disease following prior therapy
which included an anthracycline, a taxane and trastuzumab
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(Geyer et al, 2006; Cameron et al, 2008). Subjects were randomised
to receive either of the following treatments:
 Lapatinib 1250 mg daily without interruption and capecitabine
2000 mg m2 per day, days 1 through 14, every 21 days; or
 Capecitabine 2500 mg m2 per day, days 1– 14, every 21 days.
Study enrollment was stopped early based on the unanimous
recommendation of the independent data monitoring committee
following a planned interim analysis. Based on independently
reviewed imaging, the primary end point of time-to-progression
had exceeded the predetermined stopping criteria, and review of
toxicity data indicated no substantive safety concerns. The study
closed to recruitment on 3 April 2006, when the results of the
interim analysis were released and patients on monotherapy were
offered the option of receiving the combination therapy. The
analysis presented here uses data as of the lock date on 3 April
2006; thus, it does not take into account benefits that may have
accrued beyond the end of the study.
Definitions
Toxicity In the primary analysis, the toxicity (TOX) state
included all days spent with Grade 3/4 AEs after randomisation
and prior to disease progression. A day with multiple AEs was only
counted once. The TOX state comprised the total number of days
spent with AEs, regardless of when AEs started or whether gaps
occurred between AEs. Per convention, AEs occurring after
progression were not included in the TOX state. Expanded
definitions of the TOX state were examined in sensitivity analyses.
Progression-free survival The end of the time period without
symptoms of toxicity or disease progression (TWiST) is based on
progression-free survival (PFS), including events of disease
progression and deaths due to any cause. For subjects who did
not progress or die as of the last data date, PFS was censored at the
time of the last independently assessed radiological scan preceding
the initiation of any alternative anticancer therapy. If a subject had
only a baseline visit or did not have an independently reviewed
radiological scan dated prior to initiation of alternative anticancer
therapy, PFS was censored at the date of randomisation.
Utility weights For the threshold utility analysis, a matrix of
hypothetical utility weights (ui) for the TOX and REL health states
was constructed by varying utility from 0 to 1 by 0.25, resulting in
25 combinations, relative to the utility of TWiST. For treatment
comparison purposes, TWiST is used as the reference state with
utility set equal to 1, representing the highest utility that can be
expected for a patient with metastatic breast cancer.
Additionally, individual utilities were determined from patient-
reported health status on the EQ-5D (EuroQol Group, 1990), a
simple and validated questionnaire measuring five dimensions:
mobility, self-care, usual activities, pain/discomfort, and anxiety/
depression. The EQ-5D was scheduled to be completed predose on
day 1, every 6 weeks for the first 24 weeks, followed by every 12
weeks thereafter, and at withdrawal from the randomised therapy.
Patient-reported utility weights were derived from the EQ-5D
using published algorithms (AHRQ, 2005). The maximum possible
value on the EQ5D is one; utility values less than zero represent a
state evaluated as worse than death for the patient.
Statistical analysis
Estimation of health-state durations The Product-Limit Method
(Kaplan and Meier, 1958) was used to estimate the mean amount of
time in the following states:
 With toxicities after randomisation but prior to progression
(i.e., TOX),
 From randomisation to progression or death (i.e., PFS), and
 From randomisation until death from any cause (i.e., overall
survival (OS)).
Survival curves corresponding to toxicity duration, PFS, and OS
were plotted on a single graph for each treatment group. The areas
between the curves represent the restricted mean durations of
TWiST and REL as follows:
Duration of TWiST ¼ PFS time  time with toxicities; and
Duration of REL ¼ OS time  PFS time
All patients in this study had previously relapsed, so the REL state
here refers to the period after further progression. To look over the
same timeframe for both treatments, analyses were restricted to
the median overall follow-up time. This convention is required as
analyses represent areas under the curve; both treatments are
evaluated over the same period of time. The primary analysis was
performed on the intent-to-treat (ITT) population, with TOX
defined to include Grade 3/4 AEs. The results of this analysis are
reported unadjusted and then are employed during the Q-TWiST
calculation.
Calculation of Q-TWiST and threshold utility analysis Q-TWiST
for each treatment arm was calculated as follows:
Q  TWiST ¼ ðuTOXTOXÞ þ TWiST þ ðuRELRELÞ
where TOX, TWiST, and REL represent the mean estimated health-
state durations, and uTOX and uREL denote utility weights for the
TOX and REL states, respectively. Note that Q-TWiST equals the
mean OS when uTOX¼ uREL¼ 1 and equals the mean PFS when
uTOX¼ 1 and uREL¼ 0.
A threshold utility analysis was performed to illustrate which
utility combinations are expected to result in different durations of
quality-adjusted survival between treatment groups. Differences
in mean Q-TWiST between treatment groups were calculated for
each combination of hypothetical utility weights (Cole et al, 2001).
Ninety-five percent confidence intervals for the mean differences
and two-sided P-values for testing the null hypothesis of no
difference were performed, based on the normal approximation,
with s.e. calculated by bootstrapping (Glasziou et al, 1990). Points
between selected utility values can be interpolated from the
threshold utility graph.
Sensitivity analyses In two sensitivity analyses, the TOX state
was redefined to include (1) all AEs of any grade or (2) AEs
of any grade classified as treatment-related according to the
protocol.
Incorporation of observed utility data For each patient, the
average utility weight derived from EQ-5D assessments during a
health state was assigned as a per-person utility weight for the
TOX, TWiST, and REL states. If a utility weight for the TWiST state
was not available for a patient, then the predose EQ-5D score was
used. For patients who progressed (i.e., were not censored for
progression), the last EQ-5D score after progression was used for
the REL state. Patients who died on the date of progression were
assigned utility¼ 0 for the REL state. To compare groups, the
overall average utility relative to the average reported utility for the
TWiST state was used.
RESULTS
As of 3 April 2006, 399 patients were enrolled and randomised
either to lapatinib plus capecitabine (n¼ 198) or to capecitabine
alone (n¼ 201). The ITT population includes all randomised
patients, who were well balanced across treatment groups. All
Q-TWiST analysis of lapatinib combined with capecitabine
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patients had advanced or metastatic HER2þ breast cancer and
had progressive disease following prior therapy, which included an
anthracycline (97%), a taxane (97%) and/or trastuzumab (97%)
Almost all patients had metastatic disease (96%), with 78%
involving visceral lesions and 49% having lesions at three or more
sites.
During the entire study period, most patients experienced at
least one AE (96% in the lapatinib plus capecitabine group and
89% in the capecitabine only group). In the combination group,
38% (76 of 198) of patients experienced a Grade 3/4 AE prior to
progression or censoring for progression, with an average start
time of 67 days after randomisation. In the capecitabine only
group, the percentage was 36% (73 of 201), starting on average
within 55 days of randomisation.
Figure 1 shows the unweighted mean duration of each health
state. Overall median follow-up for survival was approximately 67
weeks. Average duration with Grade 3/4 AEs (prior to progression)
was less than 2 weeks, and the difference between groups was not
statistically significant. Mean time in the TWiST state (time
without severe toxicities or symptoms of progression) comprised
the primary difference in survival time between the treatment
groups. The additional 3.5 weeks of overall survival for the
combination group vs the monotherapy group was more than
accounted for by the difference in TWiST (32.1 weeks vs 21.3
weeks, Po0.0001). Partitioned survival plots appear in Figure 2.
In the primary analysis, the difference in quality-adjusted
survival time between combination and monotherapy ranged from
3 to 11 weeks (Table 1), depending on relative valuations of the
health states. Differences were statistically significant except where
REL was assumed to have a utility equal to TWiST. Thus, any
patient who places less than full utility on time after progression is
expected to gain more quality-adjusted survival with lapatinib,
regardless of what value the patient places on the TOX state. When
all states are valued at full utility (last row of Table 1), the mean
survival advantage is 3.5 weeks (P¼ 0.1556) although the survival
data is not yet fully mature. The threshold plot in Figure 3
illustrates the Q-TWiST differences between groups, with varying
combinations of utility weights for TOX and REL.
As EQ-5D can produce negative utility values, we also ran the
analyses using negative utilities for the TOX and REL states. All
comparisons resulted in a positive Q-TWiST advantage for the
LþC combination vs C monotherapy. Negative utilities on the
TOX state diminished the advantage, whereas negative utilities on
the REL state increased the advantage. In other words, the less
Table 1 Q-TWiST differences for varying combinations of utility weights
Utility per health state Expected difference in Q-TWIST
TOX TWiST REL (Weeks) P-value
0 1 0 10.8 0.0000
0.25 1 0 10.9 0.0000
0.5 1 0 11.0 0.0000
0.75 1 0 11.0 0.0000
1 1 0 11.1 0.0000
0 1 0.25 8.9 0.0002
0.25 1 0.25 9.0 0.0001
0.5 1 0.25 9.1 0.0001
0.75 1 0.25 9.1 0.0001
1 1 0.25 9.2 0.0001
0 1 0.5 7.0 0.0017
0.25 1 0.5 7.1 0.0015
0.5 1 0.5 7.2 0.0013
0.75 1 0.5 7.2 0.0012
1 1 0.5 7.3 0.0012
0.90 1 0.65 6.1 0.006
0 1 0.75 5.1 0.0239
0.25 1 0.75 5.2 0.0217
0.5 1 0.75 5.2 0.0199
0.75 1 0.75 5.3 0.0185
1 1 0.75 5.4 0.0175
0 1 1 3.2 0.1912
0.25 1 1 3.3 0.1807
0.5 1 1 3.3 0.1712
0.75 1 1 3.4 0.1629
1 1 1 3.5 0.1556
Q-TWiST¼ quality-adjusted time without symptoms of disease or toxicity of
treatment. Positive values indicate longer duration for combination therapy than
monotherapy. Highlighted row shows results using average observed utility values
relative to TWiST.
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Figure 1 Unweighted mean duration of health states (weeks).
TOX¼ toxicity state includes days with severe and life-threatening adverse
events prior to progression only; TWiST¼ time without symptoms or
toxicity; REL¼ relapse period until death or end of follow-up.
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Figure 2 Partitioned survival curves. AEs¼ adverse events; ITT¼ intent-
to-treat; TOX¼ toxicity; TWiST¼ time without symptoms or toxicity.
Q-TWiST analysis of lapatinib combined with capecitabine
B Sherrill et al
713
British Journal of Cancer (2008) 99(5), 711 – 715& 2008 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
value a patient places on time after progression, the more the
combination therapy is expected to increase quality-adjusted
time.
In the sensitivity analyses with TOX expanded to include all AEs
or treatment-related AEs of all grades, differences were slightly less
pronounced; patients in the combination group experienced AEs
for 4 –5 weeks longer than patients in the single-treatment group.
However, the quality-adjusted survival advantage of lapatinib plus
capecitabine remained statistically significant, with most utility–
weight combinations resulting in a Q-TWiST advantage for the
lapatinib plus capecitabine combination. This finding remained
despite the fact that lower grade AEs were not differentiated from
more serious AEs and utility values were applied uniformly to the
entire TOX period.
Average observed utility values for each health state are shown in
Table 2. Although 94% of patients completed at least one EQ-5D
assessment, averages are based on a smaller subset of patients. Visits
at which EQ-5D assessments were taken often did not correspond to
the timing and conditions of a given health state. Consequently,
observed utility scores for the TOX state were available for only 30%
of patients who experienced a Grade 3/4 AE. Utilities for the REL
state were based on about 30% of patients in the study.
The overall average utility value observed during the TOX state
(Grade 3/4) was 0.59, and this value was similar between groups.
Patient-reported utility weights for the TWiST states were less than
one on average, consistent with the poor health of these patients
even prior to progression. The TOX utility values ranged from
0.6 to 1.00, and REL utility values ranged from 0.23 to 1.00.
Overall observed utilities in TOX and REL were normalised relative
to a utility¼ 1 for TWiST, providing an average relative utility of
0.90 for TOX and 0.65 for REL. On the basis of these values, the
between-group Q-TWiST difference was 6.1 weeks (P¼ 0.006,
Table 1). Findings were similar when this analysis was repeated to
include only patients who contributed at least one EQ-5D value.
DISCUSSION
In the primary analysis, all hypothetical utility combinations
resulted in greater quality-adjusted survival times for the women
randomized to lapatinib plus capecitabine compared to capecita-
bine only. The difference was statistically significant, except when
the utility assigned to the REL state was more than 75% of the
utility of the TWiST state, a value greater than the average for the
patients’ own assessments in this study. Given that patients have
their own ways of valuing their time, the grid of possible values
allows an individual physician or patient to estimate what their
own experience will be using their particular circumstances and set
of values. For patients who rate the utility of both TOX and REL at
half the utility of TWiST, the combination treatment is expected to
provide an additional 7 weeks of quality-adjusted survival time
compared with capecitabine alone over a 67-week time horizon.
These results showing a quality-adjusted survival advantage for
lapatinib with capecitabine compared with capecitabine alone were
robust for the inclusion of varying grades of toxicity. As less
serious events, which were more common on the combination
arm, were given the same utility rating as more serious ones, this
sensitivity analysis is conservative and may underestimate the
magnitude of the quality-adjusted survival advantage presented by
combination therapy.
Revicki et al (2006) recommend that a clinically important
difference for Q-TWiST is approximately 10% of overall survival in
a study. Differences as low as 5% may be important for some
diseases, and differences as great as 15% are clearly important. In
this study, Q-TWiST is between 3 and 11 weeks longer (4.5–16% of
median OS) for subjects on combination therapy than for subjects
on monotherapy, depending on relative utility weightings of the
health states. When utilities for periods of toxicity and relapse
were valued at half that of TWiST or when using observed patient
utility data, the Q-TWIST difference was approximately 7 weeks,
approximately 10% of the median overall survival of 67 weeks,
which would be considered clinically important according to the
Revicki guideline.
In sensitivity analyses, with the TOX state definition expanded
to include treatment-related AEs or all AEs, the TOX state was
longer for the combination group, as would be expected. How-
ever, the quality-adjusted survival advantage of lapatinib plus
capecitabine remained evident for almost all hypothetical utility
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Figure 3 Threshold utility plot (Q-TWiST differences in weeks). Positive
numbers indicate longer Q-TWiST for patients on combination therapy.
Shading represents combinations of utility values for which the difference in
Q-TWiST is significant: medium grey, Po0.05; light band, 0.05oPo0.10;
dark grey, P40.10. AEs¼ adverse events; ITT¼ intent-to-treat;
Q-TWiST¼ quality-adjusted time without symptoms of disease or toxicity
of treatment; TOX¼ toxicity; ns¼ not significant.
Table 2 Average utility values by health state, based on EQ-5D scores
Lapatinib plus capecitabine (N¼198) Capecitabine monotherapy (N¼ 201)
Health-state ITT population n Utility n Utility
TOX: Grade 3/4 27 0.60 17 0.59
TWiST 168 0.66 157 0.66
Relapse 50 0.41 67 0.44
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combinations. Most differences were statistically significant
between groups. Differences were less pronounced only if REL
was valued at the level of TWiST or if REL was valued almost at the
level of TWiST and higher than TOX.
Patient-reported utility data from the trial was used to estimate
average utility weights for the health states. However, there are
limitations on basing quality-adjusted survival on actual patient
experience of the treatments administered. EQ-5D data were not
reported on all patients or at all visits, and fewer than half of the
patients had an end-of-study assessment. Furthermore, to use
EQ-5D data to ascribe utilities to the TOX state, the assessment
should have taken place on a day when the AE was being
experienced, and this was uncommon. REL utilities were based on
values collected at withdrawal from study treatment and could be
determined only for patients who experienced the progression
event, not for those who were censored for the event.
Despite these limitations, the overall average reported utility for
REL was 0.43, which is in the 0.41–0.69 range reported by Earle
et al (2000) for progressive metastatic breast cancer. At this level,
and with average utility for TOX and TWiST at 0.59 and 0.66,
respectively, the lapatinib plus capecitabine combination treat-
ment used in this study provides, on average, significantly more
quality-adjusted survival time than does treatment with capecita-
bine alone.
Earle et al (2000) also report utility in the range of 0.16– 0.54 for
terminal metastatic breast cancer, and Nooij et al (2003) cite a
physician-based utility¼ 0.23 for the progressive state in meta-
static breast cancer. These lower values may reflect a more realistic
range of values than the observed values for the entire period after
progression, as the deterioration in health that eventually occurs
may not be captured well by assessments that were taken close to
the progression date. Application of lower utilities for the REL
state would result in a more pronounced Q-TWiST advantage for
the lapatinib plus capecitabine treatment combination.
In summary, the lapatinib plus capecitabine combination
provided significantly greater Q-TWiST than did capecitabine
alone. The full impact of the combination cannot be determined,
because of the early closure to accrual and subsequent cross over,
but it is likely that the average 7 weeks improvement is an
underestimate of the overall benefit.
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